Introduction warts or papillomas. Cutaneous warts are often found on the hands and feet of 7-10% of the general population and, although cosmetically annoying, are not life-threatening.
HPV-associated genital warts or condyloma acuminata, are of substantially greater medical significance since infection with some these viruses has been strongly associated with anogenital malignancies, especially cervical cancers (zur Hausen, 1994) . Even though genital infection with HPV is not a reportable disease, the Centers for Disease Control and Prevention estimates that over one million new cases are diagnosed annually in the US (Dalence, 1993) . That incidence would rank HPV as the most common sexually transmitted viral agent in the USA and the UK (Becker et al., 1987) with 5-20% of persons aged 15-49 years old positive for the presence of HPV DNA (Nuovo et al., 1990) . In one study using highly sensitive polymerase chain reaction (PCR) detection, women attending college in the USA demonstrated a >40% prevalence of HPV infection (Bauer et al., 1991) . In the USA, the number of physician visits for treatment of genital warts was reported at over one million in 1984, and continued to increase to 1.5 million annual visits in the late 1980s (Shah & Howley, 1996) . Furthermore, it has been reported that two-thirds of the sexual partners of those with genital warts will become infected within several months following exposure (Oriel, 1971) .
The genital-associated HPVs are typically classified as either 'low risk' or 'high risk' based on their association with malignant progression. HPV types 6 or 11 which are found in >90% of benign genital lesions may spontaneously regress or persist for years, and are considered to be low risk for progression to malignancy (zur Hausen & Schneider, 1987) . HPV-6 and -11 are also associated with laryngeal papillomatosis (Gissmann et al., 1982 (Gissmann et al., , 1983 , a rare but debilitating disease, characterized by the often rapid growth of benign epithelial tumours on the larynx. The HPVs in the 'high-risk' group include types 16, 18, 31, 33, 35 and are found in moderate to severe dysplasias and invasive carcinoma of the genital mucosa [for reviews see (Koutsky et al., 1988; Werness et al., 1991; zur Hausen, 1991) ]. Recent studies have found that almost 90% of cervical carcinomas contain HPV DNA (Riou et al., 1990) . Another group of HPVs with malignant potential (types 5 and 8) is associated with the rare, hereditary disease epidermodysplasia verruciformis (EV). EV patients are highly susceptible to the development of persistent cutaneous warts which, in association with exposure to sunlight, are at high risk for malignant transformation (Orth, 1987) .
Current Treatment
HPV infection is widespread in the population and is associated with a broad spectrum of human disease ranging from benign warts to invasive, metastatic and lethal cancer. In spite of this, there is currently no virus-specific drug therapy available. Although cutaneous warts in children are generally innocuous and often resolve on their own, their persistence can be aggravating. Treatment of common warts in children is often difficult because of thinner skin and a lower threshold for pain. Multiple visits utilizing a variety of treatment modalities are often required to completely eliminate the warts. Genital infections caused by 'low risk' HPV may also be self-limiting; however, the morbidity, and the economic and social costs related to HPV infection are substantial. Thus, an efficacious therapy for benign HPV disease would be very beneficial. Antiviral inhibition of high risk HPVs in benign or premalignant lesions would be expected to prevent malignant progression provided that treatment resulted in the elimination of viral DNA. Unfortunately, no virus-specific inhibitor has yet been described and current therapy for all HPV infections relies on non-specific destruction or removal of infected tissue by often painful ablative procedures.
Surgical procedures for HPV disease using cryotherapy (dry ice or liquid nitrogen), CO 2 laser therapy, electrocautery or local excision of the warty tissue have been used clinically with varying degrees of success (Beutner & Ferenczy, 1997; Krebs, 1989) . Various localized topical or intralesional treatments have been used including chemical or cytotoxic agents such as salicylic acid, trichloroacetic acid, podophyllin, colchicine, bleomycin, cantharidine and 5-fluorouracil. The antiviral agent ribavirin has been evaluated in the clinic for the treatment of laryngeal papillomatosis (McGlennen et al., 1993) . Although some treatment efficacy has been seen, adverse haematological effects related to its relatively non-specific mode of action (Canonico et al. 1984a,b) may hamper the development of ribavirin as a therapeutic agent for HPV. Immune stimulatory agents have also been pursued in the hope that these therapies would induce a systemic immunological response mimicking the response seen when benign lesions undergo spontaneous regression. Studies with systemic and intralesional interferon have resulted in mixed success in the treatment of genital and laryngeal warts (Trofatter, 1991; Tyring, 1988) . Recently, imiquimod (Aldara; 3M), which stimulates the production of interferon and interleukins, has been approved for the treatment of genital lesions (Testerman et al., 1995) . Vaccine development, both therapeutic and prophylactic, is being actively pursued by a number of groups and has been recently reviewed (Frazier, 1996) .
In addition to the rather non-specific modes of action for the treatments mentioned above, patients often experience a high rate of recurrence (30-90%) following therapy. Thus, a successful therapy must both eliminate the primary lesion and prevent recurrence. It is clear from the high prevalence of HPV infection in the population (and the strong epidemiological association between genital cancers and HPV) that there is a significant unmet medical need for an effective, specific and safe therapy for infections caused by HPV.
Life Cycle and Genomic Organization
Papillomaviruses infect basal cells of the epithelium and are very host-and tissue-specific. Gene expression and virion production are tightly linked to the differentiation state of the epithelial cell. Human skin is continuously being renewed through a small sub-population of basal cells or keratinocyte stem cells. As terminally differentiated cells of the stratum corneum are shed from the skin surface, they are replaced with less differentiated cells from the stratum granulosum and stratum spinosum. A typical infection of a basal cell with human papillomavirus is illustrated in Figure 1 . In an incompletely understood process, HPV infects basal stem cells, providing a continuous source of infected cells.
It is generally thought that infection of the basal epithelial cells occurs following microtrauma to the skin. Although a specific receptor for HPV has not yet been unequivocally identified, Evander et al. (1997) used viruslike particles (VLPs; see discussion of L1/L2) to infect CV-1 and HaCat epithelial cells to show that the α6 integrin subunit may act as a receptor for HPV infection. Integrins Infection is thought to occur through physical trauma (microwound) to the epithelium allowing access of individual virus particles to the basal cells. Viral DNA is maintained in the basal cells and persists in the overlying, differentiated stratum spinosum. High levels of viral DNA replication is typically only seen in the stratum granulosum and stratum corneum where viral capsids begin to be expressed and assembled. Intact virus particles are sloughed from the surface during the normal process of epithelial turnover. (b) Cellular events during HPV infection. Virus particles infect basal cells, become uncoated in the cytoplasm, and viral DNA is established as an independent replicon in the nucleus of the infected cell. Replication requires the expression of the E1 and E2 viral proteins translated from polyadenylated, cytoplasmic mRNA. Viral oncoproteins E5, E6, and E7 are made in the suprabasal layers and are believed to perturb the normal program of epithelial differentiation. Late gene expression of the major (L1) and minor (L2) capsid proteins occurs in the upper layers of the epidermis. are cell surface glycoproteins involved in intracellular adhesion and attachment of basal cells to the basement membrane. Despite α 6 β 4 integrin presence on the surface of many types of cells, in skin, its expression is limited to basal cells of stratified squamous epithelium (Carter et al., 1990a; DeLuca et al., 1990; Kajiji et al., 1989; Sonnenberg et al., 1991; Tennenbaum et al., 1996) . Almost all basal cells express high levels of α 6 β 4 integrin complex (Carter et al., 1990b,c; Peltonen et al., 1989) and recently, Li et al. (1998) have further distinguished keratinocyte stem cells from other basal cells through detection of a cell-surface antigen reactive against a monoclonal antibody (Mab10G7). Further characterization of keratinocyte stem cell surface antigens may allow preparation of uniform cell populations for detailed study of HPV infection; the identification of an HPV receptor would permit compound screening for agonists/antagonists that prevent virus infection. Following infection, uncoating and movement of the HPV genome to the nucleus, the virus establishes its genome at roughly 20-100 copies per cell. The viral DNA copy number remains constant as replication occurs in synchrony with the cell division program of the infected basal cell. HPV alters the normal differentiation process of the epidermis in several ways. Perhaps most apparent, is an expansion of the stratum spinosum layer resulting in an overall thickening of the skin. HPV stimulates cell proliferation in the stratum spinosum through the early expression of the immortalizing and transforming functions of the E6 and E7 proteins. As the infected cells begin to differentiate, viral DNA synthesis increases and is maximal in the stratum granulosum layer. Late gene expression of the L1 and L2 proteins occurs in the uppermost stratum corneum where virus particles are assembled and released from the cell.
Because replication of HPV requires a differentiating epithelial cell, propagation in the laboratory has been very difficult and limited. Small numbers of virus particles have been produced using phorbol ester-treated organotypic cultures which mimic the normal differentiation pattern of epithelial cells (Frattini et al., 1997; Meyers et al., 1992) . Recently, a W12 cell line which stably maintains episomal HPV-16 DNA has been induced to produce virus particles after treatment with calcium and serum (Flores & Lambert, 1997) . Other methods for producing virus particles include transplanting HPV-infected tissue under the renal capsule (Kreider et al., 1985) or under the skin of an immunocompromised mouse (Bonnez et al., 1998) .
In the 1970s, the first truly effective antiviral drugs were discovered using conventional cell culture techniques in which cells were infected with virus, treated with candidate compounds and observed for any antiviral effect. The combination of molecular biology techniques of the 1980s and the technological advances of the 1990s, have allowed pharmaceutical companies to dramatically broaden their antiviral compound screening programmes. Advances in combinatorial chemistry, miniaturization of assay formats, highly sensitive detection methods, and computer-assisted automation and robotics, have together enabled high-throughput screening of many diverse viral targets. Instead of screening against infectious virus particles using conventional cell culture techniques as has been done in the past, viruses are being genetically dissected to find specific inhibitors of virusencoded gene products. Consequently, discovering antivirals effective in inhibiting more difficult viruses such as HPV is much more feasible than it was in the past. Animal models for HPV are adequate and available to characterize the efficacy and pharmacokinetics of prospective antiviral therapies (for a review, see Stanley et al., 1997) .
Molecular Targets of HPV
Human papillomaviruses contain approximately 8 kb of double-stranded, covalently closed, circular DNA, encod- ing approximately eight distinct proteins. These proteins can be characterized as either early (E) or late (L) genes, depending on when they are expressed relative to viral DNA replication (Fig. 2) . Regulatory sequences and the origin of replication are contained in the non-coding, long control region (LCR). A description of the virally encoded proteins, interacting cellular factors and the prospect of each of these targets for antiviral inhibition is outlined below.
E5 oncoprotein
The E5 ORF of bovine papillomavirus (BPV) encodes a membrane-associated, 44 amino acid polypeptide which efficiently transforms rodent cells in culture (Burkhardt et al., 1987; DiMaio et al., 1986) . The hydrophobic amino terminus is thought to be responsible for localization of E5 to intracellular membranes including those of the endoplasmic reticulum and Golgi apparatus. The E5 protein does not appear to possess any intrinsic enzymatic activity, instead it exerts its growth stimulatory effects through direct interactions with host proteins. E5 has been shown to interact specifically with the receptor for platelet-derived growth factor-β (PDGF-β) (Nilson & DiMaio, 1993) and with the 16 kDa membrane component of the vacuolar H + ATPase (Goldstein et al., 1991) . Direct association between BPV E5 and the PDGF-β receptor leads to an increased level of receptor autophosphorylation and tyrosine kinase activity (Petti & DiMaio, 1994; Petti et al., 1991) .
Although the primary amino acid sequence of the E5 ORF of BPV is not conserved in the HPVs, the comparable ORF exists with regard to position in the genome. HPV E5 is typically twice as long; around 70-90 residues (compared to 44 amino acids for BPV-1 and -2). A somewhat weak cellular transformation capacity has been demonstrated for E5 genes from HPV-16, HPV-6 and HPV-11, which can be enhanced by the addition of epidermal growth factor (EGF) (Chen & Mounts, 1990; Chen et al., 1994; Leechanachai et al., 1992; Pim et al., 1992; Straight et al., 1993) . HPV-16 E5 has been shown to cooperate with HPV-16 E7 in growth stimulation and transformation of rodent cells (Bouvard et al., 1994; Valle & Banks, 1995) , and to enhance keratinocyte immortalization by HPV-16 E6 and E7 (Stoppler et al., 1996) . Furthermore, expression of HPV-16 E5 in a human keratinocyte line (HaCaT) interfered with cell-cell communication through gap junctions (Oelze et al., 1995) .
Both HPV-16 E5 and HPV-6 E5a can form complexes with the 16 kDa vacuolar H + ATPase as originally described for BPV E5 (Conrad et al., 1993) and through that interaction may inhibit acidification of endosomes which are important for EGF receptor processing (Straight et al., 1995) . Numerous cell growth studies have observed some degree of cooperativity between HPV E5 and EGF, and have suggested that phosphorylation of EGF receptors is greater in the presence of EGF and E5 than with EGF alone (Straight et al., 1993) . Thus, if the major role of HPV E5 is to disrupt receptor ligand-dependent cellular signalling, a potential therapeutic avenue could focus on restoration of the normal receptor cycling pathway through endosomes. Based on this potential mechanism for the activity of HPV E5, an antagonist of E5 or an agonist that targets the proton pump might have therapeutic utility in HPV-infected cells.
There are some conflicting data which suggest that HPV E5 may directly interact with growth factor receptors such as EGFR and erbB2 (Conrad et al., 1994; Hwang et al., 1995) . If this interaction is critical to the activity of E5, then it may be possible to target this interface for antiviral intervention through the identification of small molecules which interfere with this protein-protein interaction. Furthermore, if activation of the EGFR pathway is critical to virus growth, potent inhibitors of the EGFR tyrosine kinase which have been recently described (Levitzki & Gazit, 1995) may show some antiviral or antitumour properties, albeit non-specific (Hu et al., 1997) .
It should be noted however, for any therapeutic modality focused on the activities of HPV E5, that in cervical cancers, E5 is normally deleted through viral integration. Therefore, the growth-stimulatory activities must be important only within benign papillomas or premalignant neoplasias and be dispensable for HPV-associated cancer. Furthermore, any small molecule inhibitors of E5 which directly associate with the viral protein may not show broad activity across the large number of HPV genotypes since E5 is rather poorly conserved.
E6 oncoprotein
Mucosal high-risk (e.g. types 16 and 18) HPV E6 and E7 can cooperate to immortalize primary human fibroblasts or keratinocytes (Hawley-Nelson et al., 1989; Münger et al., 1989a; Watanabe et al., 1989) and HPV-16 E6 alone can immortalize human mammary epithelial cells (Band et al., 1990 (Band et al., , 1991 . In general, the transforming or immortalizing activities of the cutaneous HPVs (Watts et al., 1984) have not been extensively studied. Among the HPVs associated with malignancies in patients with epidermodysplasia verruciformis, HPV-8 E6 has been shown to transform cultured rodent cells, C127 and Rat-1 (Iftner et al., 1988) . Using retrovirus-mediated transduction, a variety of cutaneous HPV E6 genes were examined for morphological transformation of rat 3Y1 cells and it was observed that malignant-associated HPV types 5, 8 and 47 had a somewhat greater capacity for cellular transformation than benign-associated types 14, 21 and 25 (Kiyono et al., 1992) . Under these conditions, cutaneous HPV-1 E6 showed no transforming activity.
Like simian virus 40 (SV40) T antigen (TAg) and adenovirus E1B, the mucosal high-risk E6 proteins can enter into complexes with the cellular p53 molecule (Fig. 3) . As a consequence of interaction with TAg and E1B, p53 is sequestered into inactive complexes which substantially extends the intracellular half-life resulting in high levels of p53 in transformed cells (for review, see Ko & Prives, 1996) . In contrast, in HPV-infected cells, the p53 levels are quite low (Hubbert et al., 1992; Scheffner et al., 1991) . High-risk HPV E6 associates with p53, but rather than sequestering p53 to inactive complexes, instead, E6 mediates an accelerated, ubiquitin-dependent degradation (Scheffner et al., 1990) . Although the actual mechanisms differ somewhat between TAg, E1B and HPV E6, the result is the same, p53 is transiently inactivated. Thus, a conserved theme is plainly apparent among the small DNA tumour viruses that inactivation of the p53 pathway in infected cells is an important step in the life cycle of these viruses.
Binding of high-risk HPV E6 to p53 is mediated by a second, 100 kDa cellular protein, E6AP (Huibregtse et al., 1991 (Huibregtse et al., , 1993a . E6AP is a member of a family of related cellular proteins and can directly bind HPV E6 in the absence of p53 although E6AP is apparently not able to associate with p53 in the absence of HPV E6 (Huibregtse et al., 1993b) . The ternary association of HPV E6 with E6AP and p53 leads to the ubiquitination and proteolytic degradation of p53 (Scheffner et al., 1990) . In the E6-dependent ubiquitination of p53, the role of E6AP is to function as an E3-like ubiquitin ligase transfering the high-energy thioester linked ubiquitin from the E2 ubiquitin subunit to an ε-amino group of a lysine on p53 (Huibregtse & Beaudenon, 1996; Scheffner et al., 1995) . Covalent attachment of multiple units of the 76 amino acid ubiquitin polypeptide to p53 leads to recognition and degradation by the 26S proteasome. The catalytic efficiency of the covalent transfer of the E6AP thioester is not substantially affected by the presence of HPV E6, suggesting that the major role of E6 is to activate binding of p53 by E6AP. It is not yet clear whether p53 is normally a substrate for E6AP-mediated ubiquitination in uninfected cells; however, it has been observed that specific inhibitors of the 26S proteasome can induce stabilization of p53 (Maki et al., 1996) .
The ability to bind and induce degradation of p53 is not completely conserved among the papillomaviruses. Although cottontail rabbit papillomavirus (CRPV) and BPV E6 proteins can induce morphological transformation of cells in culture, they are both apparently unable to associate with p53 (Harry & Wettstein, 1996; Werness et al., 1990) . The E6 proteins from the cutaneous HPVs have not been looked at extensively but HPV-8 is unable to bind and destabilize p53 (Steger & Pfister, 1992) . Among the mucosatropic HPVs, it is perhaps most intriguing that HPV types 6 and 11 which are associated with a low risk for malignant progression, express E6 proteins that are also unable to efficiently bind and destabilize p53 (Scheffner et al., 1990; Werness et al., 1990) . A clear correlation exists among the mucosatropic HPVs between the capabilities to immortalize human keratinocytes and destabilize p53, and their association with human malignancy.
Additional cellular proteins that interact with E6 have been described recently (Fig. 3 ). E6BP was identified through yeast two-hybrid analysis and binds in vitro to E6 proteins from HPV-16 and -18 (Chen et al., 1995) . E6BP was found to be identical to ERC-55, a putative calciumbinding protein localized to the endoplasmic reticulum (Weis et al., 1994) . This potential association is of particular interest due to the role of calcium ions in cell proliferation and keratinocyte differentiation. As with p53, this interaction appears to be specific to the high-risk E6 proteins as those from HPV types 6 and 11 do not directly interact with ERC-55. In addition, it has been recently shown that E6 proteins from BPV-1 as well as those from HPV-16 and -18 will interact both in vitro and in vivo with paxillin . Interaction with E6 interferes with paxillin binding to vinculin and the focal adhesion kinase (FAK) and is potentially responsible for E6-mediated disruption of the actin cytoskeletal network. In addition, high-risk E6 has been shown to interact with hDLG, a protein known to interact with the adenomatous polyposis coli (APC) tumour sup-
Figure 3. HPV E6 Interactions
Protein interactions between high risk HPV E6 and various cellular proteins. The interactions that have been demonstrated both in vitro and in vivo are depicted by the block arrow while those putative interactions thus far only seen in vitro are depicted by the dashed arrows. HPV E6 enters into a trimeric complex with two cellular proteins, E6AP and p53 leading to the enzymatic addition of chains of ubiquitin (U-U-U-U) marking p53 for proteolytic digestion. Additional interactions have been described through yeast twohybrid experiments indicating that HPV E6 can interact with paxillin, hDLG, and E6BP. References for the interactions are included in the text.
p53 Degradation pressor gene which is mutated in most colon cancers (Kiyono et al., 1997; Lee et al., 1997) .
Antiviral strategies to target E6-mediated functions might be accomplished in one of several ways. Inhibitory molecules could act directly to block the association of E6 with one of its cellular partners including E6AP, E6BP, paxillin, or other as yet unidentified proteins. The identification of a small molecule which specifically and avidly interferes at these interfaces would probably be a difficult task based on related experiences with other protein-protein interactions (Huber et al., 1994) . Alternatively, critical cellular pathways that are modulated by E6 could be targeted for intervention downstream of the E6 interaction. For example, p53 degradation could theoretically be prevented through the development of inhibitors of E6:E6 AP-mediated ubiquitination and proteolysis (Waddell & Jenkins, 1998) . Alternatively, it may be possible to alter the pathways associated with cytoskeletal signalling through modulation of regulatory tyrosine kinases, or potentially alter the movement of Ca 2+ ions putatively associated with the regulation of E6BP or ERC-55. To date, the only interactions described between HPV E6 and cellular proteins have been limited to the high-risk mucosatropic viruses. Thus far, no specific interactions with cellular proteins have been described for the E6 proteins of the cutaneous or low-risk mucosal HPVs. Consequently, any therapies based upon inhibition of the currently known activities of E6 would likely be limited to treatment of high-risk HPV infections.
E7 oncoprotein
The E7 protein encoded by the high-risk HPVs is a small, nuclear phosphoprotein of ~100 amino acids that can act in partnership with E6 for the immortalization of primary human keratinocytes. The earliest indications of the biological activities of E7 came from studies which showed that HPV-16 could cooperate with an activated ras oncogene in the transformation of primary rodent cells (Matlashewski et al., 1987) , and that E7 could transcriptionally activate an adenovirus (Ad) early promoter (Phelps et al., 1988) . These seemingly disparate observations were unified through recognition that E7 encoded both functional and structural similarities to the Ad E1a protein (Phelps et al., 1988) , and that the cellular transforming properties were correlated to the ability of E7 to associate with the retinoblastoma (RB) protein (Dyson et al., 1989) (Fig. 4) . Binding of E7 to the RB protein causes release of the E2F transcription factor (Chellappan et al., 1992; Phelps et al., 1991) , which in addition to stimulating the Ad E2 promoter, acts on the promoter elements of a number of S phase-specific cellular genes including thymidine kinase, thymidylate synthase, DNA polymerase α , dihydrofolate reductase, c-myc, cdc2, and ribonucleotide reductase (Farnham et al., 1993; Nevins, 1992) . The expression of E7, like E6 discussed above, is critical to HPV replication since the viruses do not encode enzymes for nucleotide anabolism during DNA synthesis. Instead, HPV genomic replication is entirely dependent on the host synthetic machinery that is normally expressed during S phase of the cell cycle. Since HPV infection occurs in the context of terminal differentiation of keratinocytes, to replicate its genome, HPVs must restrain epithelial differentiation to sustain the expression of the host cell's replicative machinery. Subordination of terminal differentiation is thought to be accomplished through the coordinated activities of E6 and E7.
A number of specific biological properties have been associated with E7 expression in cells including abrogation of TGF-α induced growth inhibition (Pietenpol et al., 1990) , abrogation of p53-mediated growth arrest (Demers et al., 1994; Slebos et al., 1994; Vousden et al., 1993) , inactivation of cyclin-dependent kinase inhibitors (Funk et al., 1997; Jones et al., 1997a; Zerfass-Thome et al., 1996) and destabilization of pRB (Boyer et al., 1996; Jones & Munger, 1997; Jones et al., 1997b) . Inappropriate expression of HPV-16 E7 in transgenic mice from tissue-specific promoters causes epidermal hyperplasia and tumour induction (Arbeit et al., 1993; Auewarakul et al., 1994; Griep et al., 1993) . The vast majority of studies of the activities of the HPV E7 proteins have been conducted with the high-and low-risk mucosae-associated HPVs; much less is known about the corresponding functions of the E7 proteins of the cutaneous HPVs (Hiraiwa et al., 1993 (Hiraiwa et al., , 1996 Schmitt et al., 1994; Watanabe et al., 1992) .
In addition to the well-described ability of E7 to interact with the RB family of proteins ( Fig. 4) , E7 association with several other cellular proteins has been described during the last few years. Interactions with basal transcription factors have been noted including TATA binding protein (TBP) and a TBP-associated protein, TAF-110 (Massimi et al., 1996; Mazzarelli et al., 1995; Phillips & Vousden, 1997) . E7 has also been demonstrated to activate the AP-1 family of transcription factors through direct interaction with the carboxyl terminus of E7 (Antimore et al., 1996) . Recent studies have also suggested that E6 and E7 may interfere with the cellular response to interferon (IFN) through suppression of IFN-inducible genes (Arany et al., 1995; Perea et al., 1997) . Use of yeast two-hybrid screening will undoubtedly continue to provide new potential interactors of the HPV E7 proteins such as S4 subunit of the 26S proteasome (Berezutskaya & Bagchi, 1997) and the human homologue of the Drosophila tumour suppressor protein, Tid56 (Schilling et al., 1998) .
The E7 proteins encoded by HPVs are non-enzymatic and apparently mediate all of their effects on cell growth through reversibly entering into a variety of protein complexes that regulate signal transduction. Both the high-and low-risk E7s interact with the RB family of proteins albeit with somewhat different affinities (Ciccolini et al., 1994; Hu et al., 1995; Münger et al., 1989b; Wu et al., 1993) . Ideally, antiviral intervention should be focused on the dis-ruption of E7-containing macromolecular complexes through direct binding of a small molecule to either E7 or its cellular target. Binding of small molecules to cellular targets is somewhat less desirable, as this is likely to affect normal cell growth since the cellular partners of E6 and E7 include important regulators of cell division; thus, many such molecules will be toxic in vivo. The E7 protein itself is an attractive target for rational drug design as it can be readily expressed and purified (Pahel et al., 1993; Imai et al., 1991) and its small size should render it a good candidate for solution of its three-dimensional structure. Unfortunately however, conditions have not yet been found which sufficiently stabilize the tertiary structure to permit solution by X-ray diffraction or multidimensional NMR (WC Phelps, unpublished data). Very recently, a crystal structure of the RB 'pocket' was derived through inclusion of a nine amino acid peptide derived from HPV-16 E7 (Lee et al., 1998) . The peptide fragment of E7 binds in a shallow groove on the RB protein, and is stabilized through a complex of van der Waal's and hydrogen bond interactions covering a surface area of approximately 1150 Å 2 . Thus far, attempts to identify specific inhibitors of the E7-RB interaction have not been successful (Huber et al., 1994) .
E2 Transcriptional modulator
The E2 gene product is an approximately 50 kDa protein that regulates the expression of several viral genes (McBride et al., 1991; Spalholz et al., 1985; Thierry & Yaniv, 1987) and, in association with E1, is required for viral DNA replication (Blitz & Laimins, 1991; . Mutations in E2 are pleiotropic and result in disruptions of replication, transcription and transformation functions (McBride et al., 1991) . Furthermore, using plasmid cloned viral DNA to induce benign lesions in the CRPV animal model system, it has been shown that intact E1 and E2 genes are both required for induction of warts (Wu et al., 1994) . The essential roles associated with the E2 protein make it an attractive target for antiviral therapies.
E2 is a site-specific DNA binding protein that dimerizes spontaneously in the absence of DNA (McBride et al., 1989; Prakash et al., 1992) and interacts directly with 12 nucleotide pair palindromic sequences found at conserved locations in all PVs (Fig. 5) . The consensus E2 recognition sequence, ACCN 6 GGT (Androphy et al., 1987; Moskaluk & Bastia, 1987) , is found in multiple copies in the LCR with at least one copy required within the minimal origin of replication (McShan & Wilson, 1997; Russell & Botchan, 1995; Ustav et al., 1993) . The total number of E2 binding sites encoded varies between PV groups, in part as a reflection of subtle divergence in patterns of viral gene expression. Through this binding, E2 can function as both a transcriptional activator and repressor (Cripe et al., 1987; Lambert et al., 1987; Phelps & Howley, 1987; Spalholz et al., 1985; Thierry & Yaniv, 1987) probably by interaction with cellular transcription factors such as SP1 and TBP (Ham et al., 1994; Li et al., 1991) .
In addition to the primary activity of E2 as a transcriptional modulator, E2 can act as an auxiliary factor for viral DNA replication. Through direct interaction with E1, E2 is believed to enhance localization of E1 to the origin of replication (Lusky et al., 1993; Mohr et al., 1990; Yang et al., 1991) . E1 has only a weak affinity for its cognate binding site whereas in contrast, E2 binds both avidly and specifically to the E2 binding site. In both transient and stable replication studies, expression of E2 (together with E1) is required, whereas in cell-free replication assays, E2 stimulates replication at low levels of E1 (Kuo et al., 1994; Muller et al., 1994; . Further, E2 binding has been shown to alleviate repression of viral DNA replication which results from nucleosome packing of the viral DNA in nuclear chromatin (Li & Botchan, 1994) . Very recently it has been shown that BPV E2 can associate with mitotic chromosomes and potentially act to facilitate uniform partitioning of episomal viral genomes to daughter cells during cell division (Skiadopoulos & McBride, 1998) .
The E2 protein is organized into two functional domains: the N-terminal domain, involved in viral transactivation, chromatin association, and direct association with the E1 protein; and a C-terminal domain involved in DNA binding and dimerization. These two functional domains are separated by a somewhat poorly conserved central hinge region of variable length (Giri & Yaniv, 1988; McBride et al., 1991; Prakash et al., 1992) . The crystal structure for the C-terminal DNA binding domain of BPV E2 (Hegde et al., 1992) and the NMR structure of HPV-31 E2 (Liang et al., 1996) bound to a double-stranded palindromic recognition sequence have been solved. These high-resolution structures may provide an opportunity for the rational design of inhibitors of the replication and transcription functions associated with the highly conserved dimerization and DNA binding domains of E2. Targeting the dimerization interface of E2 for inhibition would likely be quite challenging since the two subunits interact through an extensive hydrophobic core that is >2500 Å 2 in size (Hegde et al., 1992) . Similarly, the DNA binding interaction is stabilized through an extensive network of base-specific interactions coupled with 48 direct and water-mediated contacts to the phosphate backbone. The net result of these interactions is a high affinity and stable protein-DNA complex with a low to sub-nanomolar K D (Alexander & Phelps, 1996; Monini et al., 1991; Muller et al., 1997; Sanders & Maitland, 1994) . Recently, Hajduk et al. (1997) have identified a small molecule inhibitor of E2-DNA binding with low µM activity using a 'structure-activity relationship by nuclear magnetic resonance spectroscopy' (SAR by NMR) approach. Discovery of compounds that inhibit E2-DNA binding would be expected to inhibit transcriptional modulatory functions and viral DNA replication. Since some E2 proteins are qualitatively interchangeable in functional assays (Chiang et al., 1992) , an inhibitor may be useful in the treatment of disease caused by a broad range of HPVs.
Inhibitors of E2 DNA binding may also have broader therapeutic use as the core DNA binding domain of the EBNA1 protein of Epstein-Barr virus is structurally homologous to that of BPV E2 (Bochkarev et al., 1996) .
E1 origin binding helicase
E1 is a 72 kDa phosphoprotein and is the most highly conserved of all papillomavirus proteins. E1 encodes the only enzymatic function of the virus, a DNA helicase. Although there are no current antiviral therapies specifically targeting a viral helicase, it remains a very viable target for inhibiting HPV and other viruses. Indeed, small molecule inhibitors of the herpes simplex virus (HSV) UL5 helicase have been described recently (Anonymous, 1996) which show antiviral activity when assayed in HSV-infected cells. An inhibitor of E1 would likely be broad-based, acting on most HPV types as the general mechanism of viral DNA replication is thought to be well conserved (Lu et al., 1993; McShan & Wilson, 1997; Remm et al., 1992; Russell & Botchan, 1995; Sverdrup & Khan, 1994; Ustav et al., , 1993 . E1 and E2 can function to replicate plasmid DNA containing heterologous animal and human PV origins of replication, and heterologous mixes of E1 and E2 proteins will support origin-dependent PV replication (Chiang et al., 1992; Del Vecchio et al., 1992; Gopalakrishnan & Khan, 1994; Kuo et al., 1994; Zou et al., 1998) . Helicases, with their associated ATPase function, are very common in prokaryotic and eukaryotic cells, as well as in most viruses. Based on amino acid sequence homology, HPV E1 has been grouped into helicase superfamily III (Koonin, 1993) along with TAg of SV40 and polyomavirus, and the NS-1 or Rep helicase of parvoviruses. E1 encodes the conserved NTP-binding motifs referred to as the Walker A and B boxes, and a third C box that is unique to superfamily III. The ATPase and nucleotide binding domains of E1 are well conserved and structurally and functionally homologous to SV40 TAg (Clertant & Seif, 1984; Mansky et al., 1997) .
HPV DNA replication has been studied by a combination of transient, stable, and cell-free replication assays, and can be generalized as follows (Fig 6) . E1 acts as an initiator of replication, binding to the origin and causing localized unwinding of the DNA. E1 has a relatively low affinity and specificity for DNA binding (Sedman et al., 1997) .
E2 acts as an accessory replication protein by binding both to E1 and its palindromic binding site on the DNA, thus helping to localize E1 to the origin (Sedman & Stenlund, 1996) . The E1 and E2 DNA binding sites are in close proximity, falling within about 100 base pairs of each other. The carboxy terminus of E2 binds DNA while the amino terminus binds E1, bringing E1 to its cognate DNA binding site and thus enhancing origin-specific replication. Once E1 is bound to the origin, it multimerizes to form a hexamer around the DNA and E2 is thought to be released. Cellular replication factors such as PCNA, RPA, RFC, topoisomerase I and II, DNA polymerase α/primase, and DNA polymerase δ are recruited to the origin for assembly to an active replication complex .
In virus-infected epithelial cells, there appear to be two different modes of viral DNA replication. Following virus infection of the basal cell, viral DNA is replicated and maintained at a steady-state level of about 20-100 copies per cell. Viral DNA replication in the basal layers of the epithelium is thought to occur through a bidirectional, semiconservative mode. The low viral copy number is maintained until the cells terminally differentiate in the stratum granulosum layer where high-level amplification of the HPV genome occurs. Very recently, Flores and Lambert have observed a switch from a bidirectional or theta form of replication to a rolling circle method of replication (Flores & Lambert, 1997) . By inducing differentia-tion in two different cell lines containing episomal copies of either HPV-16 or HPV-31, they were able to observe with 2D-gel electrophoresis, a fundamental change from theta replication to rolling circle. Antiviral strategies for the inhibition of E1-dependent replication can be focused on either the NTPase or helicase activities ( Jenkins et al., 1996) . Both catalytic functions can be independently assayed using widely available formats (Matson & Kaiser-Rogers, 1990; Raney et al., 1994) . Recently, the structures of three helicases have been determined: PcrA from Bacillus, Rep from Escherichia coli, and HCV RNA helicase (Bird et al., 1998; Cho et al., 1998; Korolev et al., 1998) . With relatively straightforward assay systems and the emergence of structural information that can be used to understand and improve small molecule inhibitors, the E1 helicase represents a very attractive drug target for the development of HPV antivirals.
L1 and L2 capsid proteins
The L1 and L2 ORFs encode the capsid proteins of the PVs and their expression occurs exclusively in differentiated keratinocytes (Sterling et al., 1990; Stoler et al., 1989) . A late promoter that is active only in the differentiated layers of a wart, is responsible for transcription of these viral genes (Grassman et al., 1996; Hummel et al., 1995) . The L1 protein, the major capsid protein, is a 55 kDa protein that is highly conserved among different types of PVs, and encodes reactive epitopes for type-specific neutralization. L1 may be important in the binding of HPV to the surface of target cells since virus-like particles (VLPs) made from L1 protein only are capable of inhibiting virus attachment (Roden et al., 1994) . L2 encodes a minor capsid component of about 75 kDa that is less well conserved and contains epitopes for group-specific neutralization. Recent work in protein expression systems demonstrated that L1 and L2 are capable of self-assembly into VLPs at a ratio of approximately 30:1 (Kirnbauer et al., 1993; Zhou et al., 1993) . Although these efforts were designed for VLP production for use in vaccination studies (for review, see Frazier, 1996) , this controlled protein assembly process could be used to screen for inhibitors of HPV virion assembly or uncoating (McCarthy et al., 1998) . The VLPs, in conjunction with X-ray crystallography, can be the basis for the rational design of inhibitors of viral assembly, uncoating or inhibition of the interaction between viral capsids and cellular receptors (Biblermuckelbauer et al., 1994) . A similar approach has been used to identify a hydrophobic pocket in the viral capsid of rhinovirus which acts as a binding site for antiviral compounds which prevent uncoating of the virus after entry into cells (Rossmann, 1988 (Rossmann, , 1989 (Rossmann, , 1993 . The WIN series of picornavirus inhibitors was developed using this technique (Badger et al., 1988) leading to the clinical evaluation of E2 BS E2 BS pleconaril for the treatment of picornavirus infections (Diana & Pevear, 1997) .
E4
The E4 gene product was identified in 1986 (Doorbar et al., 1986 ) but a clear understanding of the function of this protein is still elusive. The RNA transcript for E4 is a spliced product fusing a few amino acids from E1 to the E4 ORFs (Baker & Howley, 1987) . Expression results in the production of a prominant 17 kDa cytoplasmic protein (Breitburd et al., 1987) . Smaller species of the protein are also routinely found owing to proteolytic cleavage at the N terminus and multimerization through interactions at the C termini (Doorbar et al., 1988) , producing higher-order complexes. In HPV-1-induced palmar and plantar warts, E4 may account for as much as 30% of the total cellular protein (Doorbar et al., 1986) . E4 is highly divergent at the amino acid level; however, common characteristics are found among the E4 proteins of different papillomaviruses suggesting that functional conservation may exist (Doorbar et al., 1989) . All the E4s are acidic, proline-rich phosphoproteins which contain clusters of leucines in some version of an LLXLL motif. The proteins bind zinc (Roberts et al., 1994b) and are found in cytoplasmic inclusion granules. The protein can self associate through interactions mediated by the C terminus (Ashmole et al., 1998; Bryan et al., 1998; Doorbar et al., 1989) and associate with keratin filaments Sterling et al., 1993) . The LLXLL motif has been shown by deletion analysis to be crucial for the association of E4 with keratin filaments (Roberts et al., 1994a) . Although originally designated as early protein, E4 is technically a late protein since its expression coincides with the onset of vegetative viral DNA replication. E4 does not appear to be involved in cellular transformation or episomal DNA replication; instead, involvement in virus maturation or vegetative viral DNA replication has been suggested ( Jareborg & Burnett, 1991; Rogel-Gaillard et al., 1992) . A role for E4 in productive infection is also likely since levels of E4 expression correlate with those of L1 and L2 (Brown et al., 1991; Crum et al., 1990) , and a bicistronic mRNA message produces both E4 and L1 in the upper layers of the epithelium (Hummel et al., 1992; Nasseri et al., 1987; Palermo-Dilts et al., 1990) . Although E4 is poorly conserved at the amino acid sequence level, homologies are found among papillomaviruses that infect similar tissue types, which may reflect a relationship between tissue specificity and E4 (Doorbar, 1991) . The level of E4 production appears to correlate with the amount of virus produced by various HPVs with very high levels found in plantar and palmar warts that produce large numbers of virus particles. Through interaction with the keratin matrix of infected cells, E4 may play a role in virus release by altering the normal differentiation of cells, facilitating the release of virus particles. However, the data in support of an association of E4 with keratin in naturally occurring warts is less clear (Doorbar et al., 1996) . The development of an antiviral agent designed to inhibit release of virus from infected cells may be possible if this mechanism of E4-mediated cytokeratin disruption can be further clarified.
Tissue tropism and cellular differentiation
The determinants of the strict epithelial tropism displayed by the HPV are not well defined. However, it is clear that transcription of the early region of the viral genome is dependent upon a combination of several ubiquitous cellular transcription factors including AP-1, NF-1, Oct-1, YY1 and TEF-1 (Apt et al., 1993; Bauknecht et al., 1992; Chong et al., 1991) . Recent studies suggest that C/EBP β (NF-IL6) forms a novel heteromeric complex with YY1 on the HPV regulatory region (Bauknecht et al., 1996) . Since C/EBP β is regulated at a transcriptional level by IL-6, and by post-translational modifications including phosphorylation (Trautwein et al., 1993) and binding to the RB protein (Chen et al., 1996) , there may be many pathways available for therapeutic disruption of virus transcription. Some studies have concluded that retinoids can induce reduction in the copy number of PV genomes in infected keratinocytes through inhibition of viral transcription (Bernard et al., 1990) suggesting that selective regulation of nuclear receptors may be of therapeutic interest. Glucocorticoid response elements (GREs) are found in many mucosatropic HPVs (Chan et al., 1989) . For HPV-16, it has been shown that the GRE in the LCR will confer strong hormone inducibility on the p97, E6/E7 promoter (Gloss et al., 1987) . These studies suggest that steroid hormones may play a role in the expression and replication of HPVs, and that hormone agonists or antagonists might be useful in the treatment of HPV infections.
In situ analysis of virtually any HPV-infected tissue will highlight the close coordination between vertical epithelial differentiation and HPV expression and replication. The pattern of viral RNA expression and DNA replication varies across the stratified epithelium with virus particles being exclusively produced in the uppermost layers of the epidermis. HPV DNA synthesis utilizes two different modes of replication during a productive virus infection. In basal cells, HPV episomes are maintained at a relatively constant copy number through bidirectional replication once per cell cycle via theta structures. In contrast, in the upper, differentiated layers of the epithelium, a switch in the mode of replication is thought to occur resulting in dramatic genome amplification through a rolling circle mode of replication (Flores & Lambert, 1997) . The host and/or viral factors that control the switch to vegetative viral DNA replication have not yet been identified; however, it is likely that such factors are expressed in a differentiationdependent fashion. Accompanying genome amplification in the upper layers of the epithelium, late gene expression is specifically induced leading to translation of the L1 and L2 capsid proteins. The differentiation-dependent transcription factors that are responsible for this temporal induction have not been identified though inhibition of such factors would be expected to prevent assembly of infectious virus particles.
Future Perspectives
A consideration for HPV that may be unique among antiviral therapies is whether an inhibitor of HPV replication could actually promote malignant progression. This concern is derived from the observation that approximately 70% of HPV-infected cervical cancers maintain exclusively integrated, high-risk HPV DNA, and that integration favours disruption of the E1 and/or E2 viral genes (Cullen et al., 1991) . It has been proposed that disruption of E2 results in upregulation of the E6/E7 promoter (Durst et al., 1991) or extension of the mRNA half-life owing to displacement of the early viral polyadenylation site ( Jeon & Lambert, 1995) . Thus, if viral integration is a critical event in malignant progression, it is important to consider whether an inhibitor of HPV replication could either promote viral DNA integration or mimic the phenotypic results of integration.
First of all, viral integration is not required for malignant progression. Around 10% of HPV-associated cervical cancers exclusively contain extrachromosomal viral DNA. Furthermore, in rabbit carcinomas associated with CRPV infection and in human malignancies associated with HPV-5 or HPV-8 in EV patients, integration of PV DNA is not associated with malignant progression. Secondly, malignant progression of HPV-infected genital lesions seems to require many years to occur, and is typically monoclonal in nature suggesting that one or more additional somatic events are required and that those events are themselves rare. Therefore, it is conceivable that if an HPV therapy resulted in a substantial reduction in the number of infected cells, by extension, the probability of progression should also be reduced. Regardless of any of these theoretical considerations, with our current level of sophistication in the monitoring of HPV-associated genital infection, it should be possible to carefully observe any dysplastic changes that might be associated with antiviral therapy.
Finally, patients, physicians and virologists should all be very optimistic about the current state of HPV biology and the prospects for improved therapies in the next few years. Substantial advances have been made recently in our abilities to propagate HPV in cell culture systems and in animal models. Successful production of VLPs offers great hope for the development of HPV vaccines and rapid advances in combinatorial chemistry and robotics are being used by many pharmaceutical companies to search for efficacious inhibitors of HPV. Prospects are good that virus-specific treatment for HPV infections will be under clinical evaluation very soon.
